Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Sofosbuvir + ribavirin is safe and effective for people with hepatitis C who have advanced liver disease

Sofosbuvir plus ribavirin is a safe option that can lead to sustained response in people with advanced liver disease including those with decompensated cirrhosis and portal hypertension, and

Published
2 hours ago
By
Liz Highleyman
Adding interferon to nucleoside antivirals may improve response for people with chronic hepatitis B

Adding pegylated interferon to entecavir (Baraclude) led to greater hepatitis B virus (HBV) viral load decline and higher likelihood of serological response in people with HBeAg-positive chronic hepatitis

Published
9 hours ago
By
Liz Highleyman
AbbVie 3-drug combination cures 92 to 96% of hepatitis C patients with cirrhosis

The largest study of new direct-acting antivirals yet conducted in people with hepatitis C genotype 1 who have compensated cirrhosis has shown that it is possible to

Published
15 April 2014
By
Keith Alcorn
AbbVie 2-drug combination + ribavirin achieves 100% cure in previously untreated genotype 4 hepatitis C

A combination of two direct-acting antivirals developed by AbbVie cured 100% of previously untreated patients with hepatitis C genotype 4 infection when used with ribavirin, Christophe Hézode

Published
14 April 2014
By
Keith Alcorn
Sofosbuvir/ledipasvir co-formulation cures more than 90% of treatment-naive and retreated genotype 1 patients

A co-formulation of sofosbuvir and ledipasvir taken for as little as eight to twelve weeks produced high sustained response rates across the board for participants in the

Published
14 April 2014
By
Liz Highleyman
Sofosbuvir + simeprevir dual therapy shows high cure rates for hepatitis C patients with or without cirrhosis

A 12-week oral regimen of sofosbuvir (Sovaldi) plus simeprevir (Olysio) without pegylated interferon or ribavirin led to sustained virological response in 93% of people with genotype

Published
14 April 2014
By
Liz Highleyman
Viral hepatitis more deadly than HIV in Europe

Viral hepatitis, which includes hepatitis C virus (HCV) and hepatitis B virus (HBV), was blamed for nearly 90,000 deaths in 2010, while HIV claimed slightly more than 8,000 lives.

Published
14 April 2014
From
Science Daily
European liver specialists recommend 'mix-and-match' approach to new hepatitis C drugs

The European Association for the Study of the Liver (EASL) has issued new guidelines for the treatment of hepatitis C which recommend that wherever possible,

Published
11 April 2014
By
Keith Alcorn
International Liver Conference: activists demand affordable hepatitis C treatment

As the 49th International Liver Conference is officially starting, activist held a demonstration in the main hall to raise the issue of access to hepatitis C treatment in low and middle-income countries. Their protest targeted Gilead whose recently-approved direct-acting antiviral, Sovaldi, sells for USD $84,000.

Published
11 April 2014
From
HepCoalition
U.S. drug industry group defends price of Gilead hepatitis drug

The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.

Published
11 April 2014
From
Reuters
← First12345...132Next →

Filter by country